Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $845.26B · View financials
Snapshot Sep 11, 2026, 1:32 PM ET
Decision snapshot: WMT stock price vs BSX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BSX's multiple
Needs BSX P/E.
Implied fair value · at WMT's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 95% equity / 5% debt · EV / Revenue 1.23x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
WALMART INC. · implied price per share
Bear
$26.01
Base
$31.42
Bull
$38.87
BOSTON SCIENTIFIC CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
TARGET CORP
WMT vs TGT
Costco Wholesale Corporation
WMT vs COST
Amazon.com, Inc.
WMT vs AMZN
CVS Health Corporation
WMT vs CVS
Walgreens Boots Alliance, Inc.
WMT vs WBA
DOLLAR GENERAL CORP
WMT vs DG
Abbott Laboratories
WMT vs ABT
Johnson & Johnson
WMT vs JNJ
Intuitive Surgical, Inc.
WMT vs ISRG
STRYKER CORP
WMT vs SYK
ZIMMER BIOMET HOLDINGS, INC.
WMT vs ZBH
Edwards Lifesciences Corp
WMT vs EW
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe WMT can sustain a premium valuation despite 4.7% growth and 3.1% net margin, then hold; otherwise, the relative case favors caution because the P/E-based implied price of $68.00 is far below the current $115.77.
WMT trades at 40.8x P/E versus BSX at 24.9x, even though WMT’s revenue growth is far lower at 4.7% versus 19.9%. On the provided P/E-based valuation, the implied price is $68.00 versus the current $115.77, implying -41.3% downside.
Supporting Metrics
